{
  "experiment_id": "8a1aa079a982d1bb2e0b7140a798e120",
  "task_name": "narrowing_of_broad_synonyms",
  "task_hash": "9dc5c284f909400a12e111d9ec8ba4e5",
  "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
  "system_instructions": "You are a metadata curation assistant. Your task is to help improve and correct metadata \naccording to the specific instructions provided for each task. Be precise, accurate, and \nfollow the guidelines carefully.\n",
  "temperature": 0.0,
  "thinking": true,
  "tools": [],
  "timestamp": "2025-11-15T03:36:16.522779",
  "task_result": {
    "task_name": "narrowing_of_broad_synonyms",
    "num_samples": 10,
    "results": [
      {
        "sample_index": 0,
        "input": {
          "diagnosis": "Neurofibromatosis",
          "assay": "DNA sequencing",
          "tumorType": "Neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Cutaneous Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: Narrowed \"Neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" (the most common and specific form of neurofibromatosis)\n\n2. **assay**: Narrowed \"DNA sequencing\" \u2192 \"whole genome sequencing\" (the most comprehensive and specific DNA sequencing method from the available options)\n\n3. **tumorType**: Narrowed \"Neurofibroma\" \u2192 \"Cutaneous Neurofibroma\" (the most common specific subtype of neurofibroma, particularly in NF1 context)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3058,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1303
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01JzZPiaRGMAve5D9SYJRaN1",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad synonyms to more specific terms from the Target Schema:\n\n1. **diagnosis**: \"Neurofibromatosis\"\n   - This is a broad term. Looking at the enum values, I can see:\n     - \"Neurofibromatosis type 1\"\n     - \"NF2-related schwannomatosis\"\n   - \"Neurofibromatosis\" typically refers to \"Neurofibromatosis type 1\" (NF1), which is the most common form\n   - However, without more context, the most appropriate narrowing would be \"Neurofibromatosis type 1\" as it's the most common and the input doesn't specify NF2\n\n2. **assay**: \"DNA sequencing\"\n   - This is a broad term. Looking at the enum values for sequencing methods:\n     - \"whole genome sequencing\"\n     - \"whole exome sequencing\"\n     - \"targeted sequencing\"\n     - \"next generation targeted sequencing\"\n     - \"Sanger sequencing\"\n     - \"bisulfite sequencing\"\n     - \"ERR bisulfite sequencing\"\n     - \"oxBS-seq\"\n     - \"RNA-seq\"\n     - \"scRNA-seq\"\n     - \"single cell RNA-seq\"\n     - \"single-cell RNA-seq\"\n     - \"single-cell ATAC-seq\"\n     - \"lncRNA-seq\"\n     - \"miRNA-seq\"\n     - \"small RNA-seq\"\n     - \"ATAC-seq\"\n     - \"ChIP-seq\"\n     - \"NOMe-seq\"\n     - \"CAPP-seq\"\n     - \"ISO-seq\"\n     - \"single molecule real-time sequencing\"\n     - \"T cell receptor repertoire sequencing\"\n     - \"ribosome profiling\"\n     - \"whole transcriptome sequencing\"\n   - \"DNA sequencing\" is very broad. The most common comprehensive DNA sequencing would be \"whole genome sequencing\" or \"whole exome sequencing\"\n   - I'll proceed with \"whole genome sequencing\" as the most comprehensive method\n\n3. **tumorType**: \"Neurofibroma\"\n   - I'll select the most precise match from the available enum values\n   - The exact term \"Neurofibroma\" exists in the list, which provides a direct mapping\n   - This allows for precise classification without unnecessary specification\n   - However, the instructions suggest narrowing broad synonyms to more specific types\n   - Without additional context, I'll consider the most common variants like \"Cutaneous\" or \"Plexiform\" Neurofibroma\n   - Given the Neurofibromatosis type 1 context, \"Cutaneous Neurofibroma\" seems most appropriate\n   - For the assay field, \"Whole genome sequencing\" provides the most comprehensive genetic analysis\n   - Focusing on the most common form and subtype ensures precise diagnostic characterization",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Cutaneous Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: Narrowed \"Neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" (the most common and specific form of neurofibromatosis)\n\n2. **assay**: Narrowed \"DNA sequencing\" \u2192 \"whole genome sequencing\" (the most comprehensive and specific DNA sequencing method from the available options)\n\n3. **tumorType**: Narrowed \"Neurofibroma\" \u2192 \"Cutaneous Neurofibroma\" (the most common specific subtype of neurofibroma, particularly in NF1 context)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3058,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1303
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Plexiform Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3058,
          "output_tokens": 1303,
          "total_tokens": 4361
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 1,
        "input": {
          "diagnosis": "NF",
          "assay": "exome sequencing",
          "tumorType": "sarcoma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}\n```\n\n**Changes made:**\n- **diagnosis**: Narrowed \"NF\" \u2192 \"Neurofibromatosis type 1\" (the most common form of neurofibromatosis)\n- **assay**: Narrowed \"exome sequencing\" \u2192 \"whole exome sequencing\" (the precise terminology for this sequencing method)\n- **tumorType**: Corrected capitalization \"sarcoma\" \u2192 \"Sarcoma\" (matching the exact enum value)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3052,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 514
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01VcNj8i2qdJ6h4w5a81NVMb",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad synonyms to match the exact controlled terminology from the Target Schema:\n\n1. **diagnosis: \"NF\"**\n   - \"NF\" is a broad term that likely refers to Neurofibromatosis\n   - Looking at the enum values, I can see \"Neurofibromatosis type 1\" is available\n   - \"NF\" commonly refers to NF1 (Neurofibromatosis type 1)\n   - The exact value from the schema is: \"Neurofibromatosis type 1\"\n\n2. **assay: \"exome sequencing\"**\n   - \"exome sequencing\" is a broad/informal term\n   - Looking at the enum values, I can see \"whole exome sequencing\" which is the precise term for this assay\n   - The exact value from the schema is: \"whole exome sequencing\"\n\n3. **tumorType: \"sarcoma\"**\n   - \"sarcoma\" is already in the enum list\n   - But looking more carefully, I see it's lowercase in the input: \"sarcoma\"\n   - In the enum, it appears as: \"Sarcoma\" (with capital S)\n   - The exact value from the schema is: \"Sarcoma\"\n\nSo the corrected metadata should be:\n- diagnosis: \"Neurofibromatosis type 1\"\n- assay: \"whole exome sequencing\"\n- tumorType: \"Sarcoma\"",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}\n```\n\n**Changes made:**\n- **diagnosis**: Narrowed \"NF\" \u2192 \"Neurofibromatosis type 1\" (the most common form of neurofibromatosis)\n- **assay**: Narrowed \"exome sequencing\" \u2192 \"whole exome sequencing\" (the precise terminology for this sequencing method)\n- **tumorType**: Corrected capitalization \"sarcoma\" \u2192 \"Sarcoma\" (matching the exact enum value)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3052,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 514
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3052,
          "output_tokens": 514,
          "total_tokens": 3566
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 2,
        "input": {
          "diagnosis": "Neurofibromatoses",
          "assay": "assay by high throughput sequencer",
          "tumorType": "Nerve Sheath Neoplasm"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"Neurofibromatoses\" (broad, plural term for the group of disorders) \u2192 \"Neurofibromatosis type 1\" (the most common and specific form of neurofibromatosis)\n\n2. **assay**: \"assay by high throughput sequencer\" (general description of sequencing technology) \u2192 \"whole genome sequencing\" (specific high-throughput sequencing method)\n\n3. **tumorType**: \"Nerve Sheath Neoplasm\" (broad category encompassing various nerve sheath tumors) \u2192 \"Neurofibroma\" (specific type of nerve sheath tumor commonly associated with neurofibromatosis)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3067,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1398
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01YaAQDX8ey2DBgpQJ2vuSrZ",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "I need to narrow the broad synonyms in the input data to more specific, controlled terminology from the Target Schema.\n\nLet's analyze each field:\n\n1. **diagnosis**: \"Neurofibromatoses\"\n   - This is a broad term that refers to a group of genetic disorders. Looking at the enum values in the Target Schema, I can see:\n   - \"Neurofibromatosis type 1\"\n   - \"NF2-related schwannomatosis\"\n   - \"22q-related schwannomatosis\"\n   - \"LZTR1-related schwannomatosis\"\n   - \"SMARCB1-related schwannomatosis\"\n   - \"Schwannomatosis\"\n   - \"Schwannomatosis-NEC\"\n   - \"Schwannomatosis-NOS\"\n   \n   Since \"Neurofibromatoses\" is plural and refers to the general group, the most common and most likely specific diagnosis would be \"Neurofibromatosis type 1\" (NF1), which is the most common form of neurofibromatosis.\n\n2. **assay**: \"assay by high throughput sequencer\"\n   - This is a broad description of sequencing methods. Looking at the sequencing-related assays in the Target Schema:\n   - \"whole genome sequencing\"\n   - \"whole exome sequencing\"\n   - \"RNA-seq\"\n   - \"targeted sequencing\"\n   - \"next generation targeted sequencing\"\n   - \"bisulfite sequencing\"\n   - \"ERR bisulfite sequencing\"\n   - \"single cell RNA-seq\"\n   - \"scRNA-seq\"\n   - \"single-cell RNA-seq\"\n   - \"single-cell ATAC-seq\"\n   - \"ATAC-seq\"\n   - etc.\n   \n   \"Assay by high throughput sequencer\" is a very general term. The most common high-throughput sequencing assays are:\n   - \"whole genome sequencing\" (WGS)\n   - \"whole exome sequencing\" (WES)\n   - \"RNA-seq\"\n   \n   Without additional context, I'll select \"whole genome sequencing\" as it's the most comprehensive approach.\n\n3. **tumorType**: \"Nerve Sheath Neoplasm\"\n   - This broad category includes several specific tumor types in the Target Schema. I see \"Malignant Peripheral Nerve Sheath Tumor\" and \"Schwannoma\" as options.\n   \n   I also notice multiple neurofibroma variants: \"Neurofibroma\", \"Atypical Neurofibroma\", \"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\", and \"Localized Neurofibroma\".\n\nSince the diagnosis is \"Neurofibromatoses\", the most common associated tumor would be \"Neurofibroma\" - the general term for nerve sheath tumors in NF1 patients.\n\nActually, I need to reconsider my approach. The task asks me to narrow broad synonyms to more specific terms. Let me think through the most appropriate narrowing for each field:\n\n1. **diagnosis**: \"Neurofibromatoses\" \u2192 \"Neurofibromatosis type 1\" (NF1 is the most common type)\n\n2. **assay**: \"ass urofibromatosis patients.\n\nLet me reconsider the assay choice. \"High throughput sequencer\" could mean RNA-seq, WGS, or WES. I'll stick with whole genome sequencing since it provides the broadest genomic coverage without additional context pointing to a more specific method.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"Neurofibromatoses\" (broad, plural term for the group of disorders) \u2192 \"Neurofibromatosis type 1\" (the most common and specific form of neurofibromatosis)\n\n2. **assay**: \"assay by high throughput sequencer\" (general description of sequencing technology) \u2192 \"whole genome sequencing\" (specific high-throughput sequencing method)\n\n3. **tumorType**: \"Nerve Sheath Neoplasm\" (broad category encompassing various nerve sheath tumors) \u2192 \"Neurofibroma\" (specific type of nerve sheath tumor commonly associated with neurofibromatosis)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3067,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1398
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole genome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3067,
          "output_tokens": 1398,
          "total_tokens": 4465
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 3,
        "input": {
          "diagnosis": "neurocutaneous syndrome",
          "assay": "spectroscopy",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"magnetic resonance spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"neurocutaneous syndrome\" \u2192 \"Unknown\"\n   - \"Neurocutaneous syndrome\" is a broad category that encompasses multiple conditions including Neurofibromatosis type 1, NF2-related schwannomatosis, and other conditions in the enum list. Without additional specificity, the most accurate controlled term is \"Unknown\".\n\n2. **assay**: \"spectroscopy\" \u2192 \"magnetic resonance spectroscopy\"\n   - \"Spectroscopy\" is a broad analytical technique. The schema includes specific types: \"FTIR spectroscopy\" and \"magnetic resonance spectroscopy\". Given the medical/tumor research context, \"magnetic resonance spectroscopy\" is the more appropriate narrowed term for clinical applications.\n\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\"\n   - Corrected to match the exact capitalization in the controlled vocabulary (\"Unknown\" with capital U).",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3052,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 894
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01EPfFwthkEwgtk2p6s492qU",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad terms to more specific controlled terminology from the Target Schema:\n\n1. **diagnosis**: \"neurocutaneous syndrome\"\n   - This is a broad term that refers to a group of neurological disorders. Looking at the enum values, I can see several specific conditions that fall under neurocutaneous syndromes:\n     - \"Neurofibromatosis type 1\" (a neurocutaneous syndrome)\n     - \"NF2-related schwannomatosis\" (related to neurofibromatosis 2, a neurocutaneous syndrome)\n     - \"Schwannomatosis\" (a neurocutaneous syndrome)\n     - \"Noonan Syndrome\" (a neurocutaneous-related syndrome)\n   \n   However, since \"neurocutaneous syndrome\" is very broad and could refer to any of these conditions, and there's no specific information to narrow it down further, the most appropriate choice would be \"Unknown\" since we cannot determine which specific neurocutaneous syndrome it is. The enum list includes \"Unknown\" as an option.\n\n2. **assay**: \"spectroscopy\"\n   - This is a broad analytical technique. Looking at the enum, I can see:\n     - \"FTIR spectroscopy\" (Fourier-Transform Infrared spectroscopy)\n     - \"magnetic resonance spectroscopy\"\n   \n   Since \"spectroscopy\" is too general and could refer to various types, without more context, but looking at the available options, both FTIR and magnetic resonance spectroscopy are in the list. Given no additional context, I cannot determine which specific type. However, since the task is to narrow broad terms, I need to pick one. Looking at the biomedical context of the other fields (diagnosis and tumorType), \"magnetic resonance spectroscopy\" might be more appropriate for clinical/medical research, but without clear context, this is challenging. \n   \n   Actually, re-reading the instructions: \"Each field should be corrected to use more precise terminology appropriate for the specific context\". Given the medical/tumor context, \"magnetic resonance spectroscopy\" is more commonly used in medical research for tumor analysis compared to FTIR spectroscopy. \n\nI'll proceed with selecting the most precise medical spectroscopy technique available in the enum list.\n\n3. **tumorType**: \"unknown\"\n   - Looking at the enum values, I can see \"Unknown\" (with capital U) is in the list. The input has lowercase \"unknown\", but I need to use the exact value from the schema which is \"Unknown\".\n\nI'll map the broad terms to their most specific and appropriate controlled terminology, ensuring exact match with the schema's enum values.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"magnetic resonance spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"neurocutaneous syndrome\" \u2192 \"Unknown\"\n   - \"Neurocutaneous syndrome\" is a broad category that encompasses multiple conditions including Neurofibromatosis type 1, NF2-related schwannomatosis, and other conditions in the enum list. Without additional specificity, the most accurate controlled term is \"Unknown\".\n\n2. **assay**: \"spectroscopy\" \u2192 \"magnetic resonance spectroscopy\"\n   - \"Spectroscopy\" is a broad analytical technique. The schema includes specific types: \"FTIR spectroscopy\" and \"magnetic resonance spectroscopy\". Given the medical/tumor research context, \"magnetic resonance spectroscopy\" is the more appropriate narrowed term for clinical applications.\n\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\"\n   - Corrected to match the exact capitalization in the controlled vocabulary (\"Unknown\" with capital U)."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3052,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 894
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 3052,
          "output_tokens": 894,
          "total_tokens": 3946
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 4,
        "input": {
          "diagnosis": "Not Applicable",
          "assay": "immunoassay",
          "tumorType": "neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n- **tumorType**: Changed \"neurofibroma\" to \"Neurofibroma\" to match the exact controlled terminology value in the Target Schema (corrected capitalization to match the enum value exactly).",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3054,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 686
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01VHYKdhzuM6DnE2wJRYmtCy",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data to see if any terms need to be narrowed:\n\n1. **diagnosis**: \"Not Applicable\" - This is already an exact match in the enum list. No change needed.\n\n2. **assay**: \"immunoassay\" - This is already an exact match in the enum list. Looking at the schema, \"immunoassay\" is listed as one of the valid values. No change needed.\n\n3. **tumorType**: \"neurofibroma\" - Let me check the schema. I see:\n   - \"Neurofibroma\" (with capital N)\n   - \"Cutaneous Neurofibroma\"\n   - \"Cellular Neurofibroma\"\n   - \"Diffuse Infiltrating Neurofibroma\"\n   - \"Localized Neurofibroma\"\n   - \"Massive Soft Tissue Neurofibroma\"\n   - \"Neurofibroma with Degenerative Atypia\"\n   - \"Nodular Neurofibroma\"\n   - \"Plexiform Neurofibroma\"\n   - \"Subcutaneous Neurofibroma\"\n   - \"Atypical Neurofibroma\"\n\nThe input has \"neurofibroma\" (lowercase n), but the schema has \"Neurofibroma\" (capital N). Since the task is about narrowing broad synonyms and using exact controlled terminology values, I need to correct the capitalization to match the exact value in the schema.\n\nThe term \"neurofibroma\" is a broad term that could be narrowed to more specific types like \"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\", etc. However, without additional context, the most appropriate correction would be to use \"Neurofibroma\" with the proper capitalization as it appears in the schema.\n\nWait, let me re-read the task. The task says \"narrow broad synonyms\" and \"replacing broad synonyms with their narrower, more specific equivalents.\" \n\n\nI'll capitalize the term to match the controlled vocabulary exactly. Without specific details about the neurofibroma type, I'll use the generic \"Neurofibroma\" from the schema.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n- **tumorType**: Changed \"neurofibroma\" to \"Neurofibroma\" to match the exact controlled terminology value in the Target Schema (corrected capitalization to match the enum value exactly)."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3054,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 686
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Not Applicable",
          "assay": "immunohistochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3054,
          "output_tokens": 686,
          "total_tokens": 3740
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 5,
        "input": {
          "diagnosis": "neurofibromatosis",
          "assay": "plate based reporter assay",
          "tumorType": "benign neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"massively parallel reporter assay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad term to the most common specific form of neurofibromatosis (NF1)\n\n2. **assay**: \"plate based reporter assay\" \u2192 \"massively parallel reporter assay\" - Replaced the general plate-based assay description with the specific controlled vocabulary term for this type of reporter assay\n\n3. **tumorType**: \"benign neurofibroma\" \u2192 \"Neurofibroma\" - Used the precise controlled term, removing the redundant \"benign\" qualifier (as neurofibromas are by definition benign) and matching the exact enum value from the schema",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3060,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 938
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_016uraz8p2oYPSf3nvpAHXga",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad terms to more specific controlled vocabulary from the Target Schema:\n\n1. **diagnosis: \"neurofibromatosis\"**\n   - This is broad. Looking at the enum options, I can see:\n     - \"Neurofibromatosis type 1\"\n     - \"NF2-related schwannomatosis\"\n   - The most common form of neurofibromatosis is NF1, so \"Neurofibromatosis type 1\" would be the appropriate narrowing.\n\n2. **assay: \"plate based reporter assay\"**\n   - This is a broad term. Looking at the enum options, I need to find the most specific match:\n     - \"massively parallel reporter assay\" - this is a specific type of reporter assay\n     - Other plate-based assays might include various screening assays\n   - \"massively parallel reporter assay\" seems like the most appropriate specific term for a plate-based reporter assay\n\n3. **tumorType: \"benign neurofibroma\"**\n   - This is broad. Looking at the enum options for neurofibroma types:\n     - \"Neurofibroma\" (general)\n     - \"Cutaneous Neurofibroma\"\n     - \"Subcutaneous Neurofibroma\"\n     - \"Plexiform Neurofibroma\"\n     - \"Localized Neurofibroma\"\n     - \"Nodular Neurofibroma\"\n     - \"Cellular Neurofibroma\"\n     - \"Diffuse Infiltrating Neurofibroma\"\n     - \"Massive Soft Tissue Neurofibroma\"\n     - \"Atypical Neurofibroma\"\n     - \"Neurofibroma with Degenerative Atypia\"\n   - Since \"benign neurofibroma\" is broad and doesn't specify the subtype, \"Neurofibroma\" would be the appropriate controlled term that's more specific than \"benign neurofibroma\" but doesn't over-specify without additional context.\n   \nActually, I should verify my reasoning. NF1 affects roughly 1 in 3,000 people compared to NF2's much rarer occurrence, making it the statistically likely match. For the assay, \"massively parallel reporter assay\" is indeed a specific plate-based variant.\n\nThe \"benign neurofibroma\" case is interesting\u2014neurofibromas are inherently benign by definition, so adding \"benign\" is redundant. The controlled vocabulary simply uses \"Neurofibroma\" as the precise term.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"massively parallel reporter assay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad term to the most common specific form of neurofibromatosis (NF1)\n\n2. **assay**: \"plate based reporter assay\" \u2192 \"massively parallel reporter assay\" - Replaced the general plate-based assay description with the specific controlled vocabulary term for this type of reporter assay\n\n3. **tumorType**: \"benign neurofibroma\" \u2192 \"Neurofibroma\" - Used the precise controlled term, removing the redundant \"benign\" qualifier (as neurofibromas are by definition benign) and matching the exact enum value from the schema"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3060,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 938
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "cell viability assay",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3060,
          "output_tokens": 938,
          "total_tokens": 3998
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 6,
        "input": {
          "diagnosis": "RASopathy",
          "assay": "immunoassay",
          "tumorType": "NFIB"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunohistochemistry\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Rationale for narrowing:**\n\n1. **diagnosis**: \"RASopathy\" \u2192 \"Neurofibromatosis type 1\" - RASopathy is a broad term encompassing several genetic syndromes affecting the RAS/MAPK pathway. Given the tumor context (neurofibroma-related), this has been narrowed to the most common RASopathy in this domain.\n\n2. **assay**: \"immunoassay\" \u2192 \"immunohistochemistry\" - Immunoassay is a broad category of assays. For tumor tissue analysis, immunohistochemistry is a specific, commonly used technique and represents an appropriate narrowing.\n\n3. **tumorType**: \"NFIB\" \u2192 \"Neurofibroma\" - NFIB appears to be an abbreviation or code. This has been narrowed to the specific tumor type \"Neurofibroma\" which is the standard terminology from the controlled vocabulary.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3055,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1404
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01SpJrfs5AfYBvQPXT9XSMU7",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Looking at the input data, I need to narrow the broad terms to more specific ones from the controlled terminology:\n\n1. **diagnosis**: \"RASopathy\" - This is a broad term that refers to a group of genetic syndromes caused by mutations in genes in the RAS/MAPK pathway. Looking at the enum values, I can see \"Noonan Syndrome\" and \"Neurofibromatosis type 1\" which are both RASopathies. However, without more context, I cannot definitively narrow this to a specific condition. But the instruction says to narrow to more specific terms. Since \"RASopathy\" is not in the enum list at all, I need to pick the most appropriate match. Given that this is about narrowing and the context appears to be related to NF (given the \"NFIB\" tumor type), \"Neurofibromatosis type 1\" would be a reasonable narrowing. However, I should be careful - if I don't have enough information to narrow precisely, I might need to use \"Unknown\" or consider other options.\n\nActually, looking more carefully - RASopathies include NF1, Noonan Syndrome, and others. Without additional context, I cannot definitively say which specific RASopathy this is. However, the task is to narrow broad terms. Since the tumor type mentions \"NFIB\" which might relate to NF, I could narrow to \"Neurofibromatosis type 1\". But \"NFIB\" is not in the enum list either, so let me reconsider.\n\n2. **assay**: \"immunoassay\" - This is already in the enum list! So I should keep it as \"immunoassay\".\n\n3. **tumorType**: \"NFIB\" - This is not in the enum list. It could potentially stand for:\n   - Neurofibroma type B (but that's not standard terminology)\n   - Something related to the NFIB gene\n   Looking at the enum, I see various types of neurofibromas and \"NF1-Associated Tumor\", \"NF2-Associated Tumor\". Without more context, if NFIB is meant to be a neurofibroma, I could narrow to \"Neurofibroma\" as a general category. Or if it's related to NF1, it could be \"NF1-Associated Tumor\".\n   \nThe most common RASopathy in this context would likely be \"Neurofibromatosis type 1\" or \"Noonan Syndrome\". Given the tumor type reference and that this appears to be in an NF-related database, \"Neurofibromatosis type 1\" seems most appropriate. I'll map \"RASopathy\" to that specific diagnosis.\n\nFor \"NFIB\", this could represent \"Neurofibroma\" or \"NF1-Associated Tumor\". \"Neurofibroma\" appears to be the more direct narrowing from this abbreviation.\n\nActually, I should reconsider \"immunoassay\" - it's a broad category encompassing more specific techniques like ELISA, immunofluorescence, and immunohistochemistry. Without knowing the exact method used, I can't definitively select one, but the task requires narrowing broad terms.\n\nSince this appears to be tumor-related research, immunohistochemistry is commonly used for tumor analysis and would be a reasonable choice. I'll go with:\n- diagnosis: \"Neurofibromatosis type 1\"\n- assay: \"immunohistochemistry\"\n- tumorType: \"Neurofibroma\"",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunohistochemistry\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Rationale for narrowing:**\n\n1. **diagnosis**: \"RASopathy\" \u2192 \"Neurofibromatosis type 1\" - RASopathy is a broad term encompassing several genetic syndromes affecting the RAS/MAPK pathway. Given the tumor context (neurofibroma-related), this has been narrowed to the most common RASopathy in this domain.\n\n2. **assay**: \"immunoassay\" \u2192 \"immunohistochemistry\" - Immunoassay is a broad category of assays. For tumor tissue analysis, immunohistochemistry is a specific, commonly used technique and represents an appropriate narrowing.\n\n3. **tumorType**: \"NFIB\" \u2192 \"Neurofibroma\" - NFIB appears to be an abbreviation or code. This has been narrowed to the specific tumor type \"Neurofibroma\" which is the standard terminology from the controlled vocabulary."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3055,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1404
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "immunocytochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3055,
          "output_tokens": 1404,
          "total_tokens": 4459
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 7,
        "input": {
          "diagnosis": "NF",
          "assay": "medical imaging",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"conventional MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Changes made:**\n1. **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad abbreviation \"NF\" to the specific diagnosis name, as NF1 is the most commonly referenced form when using the abbreviation \"NF\"\n2. **assay**: \"medical imaging\" \u2192 \"conventional MRI\" - Narrowed the broad term \"medical imaging\" to a specific imaging modality commonly used in neurofibromatosis research and clinical practice\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\" - Corrected the capitalization to match the exact controlled terminology value in the schema",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3048,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 997
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_018DNhyUdkezBUJbyvQCG974",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Looking at the input data, I need to narrow broad synonyms to more specific, precise terms from the Target Schema:\n\n1. **diagnosis**: \"NF\" - This is a broad abbreviation that likely stands for \"Neurofibromatosis\". Looking at the enum values in the schema, I can see \"Neurofibromatosis type 1\" as an option. However, \"NF\" could also refer to NF2 (which would be \"NF2-related schwannomatosis\" in the schema). Since NF1 is more common and \"Neurofibromatosis type 1\" is explicitly listed, and without more context, I should choose the most common interpretation. However, I should also consider that \"NF\" is too broad and could be NF1 or NF2. Looking at the options:\n   - \"Neurofibromatosis type 1\"\n   - \"NF2-related schwannomatosis\"\n   \n   Since the schema doesn't have a generic \"Neurofibromatosis\" option and we need to narrow to a specific term, and NF1 is more commonly referred to as just \"NF\", I'll go with \"Neurofibromatosis type 1\". But actually, there's also \"Unknown\" as an option if we can't determine which specific type. However, the task is to \"narrow broad synonyms\" which means making them more specific. The most common usage of \"NF\" is for NF1, so \"Neurofibromatosis type 1\" is the appropriate narrowing.\n\n2. **assay**: \"medical imaging\" - This is a broad term. Looking at the enum values, there are many specific imaging techniques:\n   - \"conventional MRI\"\n   - \"structural MRI\"\n   - \"functional MRI\"\n   - \"resting state functional MRI\"\n   - \"diffusion MRI\"\n   - \"Magnetization-Prepared Rapid Gradient Echo MRI\"\n   - \"magnetic resonance angiography\"\n   - \"magnetic resonance spectroscopy\"\n   - \"ultrasound\"\n   - \"high frequency ultrasound\"\n   - \"x-ray\"\n   - \"x-ray computed tomography\"\n   - \"positron emission tomography\"\n   - \"optical coherence tomography\"\n   - \"optical tomography\"\n   \n   The most common medical imaging technique in general practice is \"conventional MRI\" or \"x-ray\", but in the context of neurofibromatosis research, MRI is the most commonly used imaging modality. I'll go with \"conventional MRI\" as it's the most general MRI option and a reasonable narrowing of \"medical imaging\" in this context.\n\n3. **tumorType**: \"unknown\" - This needs to match the exact capitalization and format in the enum. Looking at the schema, I can see \"Unknown\" (with capital U) as an option, so I'll use that exact term.\n\nI'll focus on matching the most precise and commonly used term from the available options, ensuring I'm narrowing the broad synonym to a specific, well-defined value in the schema.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"conventional MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Changes made:**\n1. **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad abbreviation \"NF\" to the specific diagnosis name, as NF1 is the most commonly referenced form when using the abbreviation \"NF\"\n2. **assay**: \"medical imaging\" \u2192 \"conventional MRI\" - Narrowed the broad term \"medical imaging\" to a specific imaging modality commonly used in neurofibromatosis research and clinical practice\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\" - Corrected the capitalization to match the exact controlled terminology value in the schema"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3048,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 997
            }
          }
        },
        "score": 1.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 3048,
          "output_tokens": 997,
          "total_tokens": 4045
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 8,
        "input": {
          "diagnosis": "neurocristopathy",
          "assay": "transcriptomics",
          "tumorType": "neurolemmoma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"RNA-seq\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"neurocristopathy\" \u2192 \"Neurofibromatosis type 1\"\n   - Neurocristopathy is a broad term for disorders of neural crest-derived tissues. Narrowed to Neurofibromatosis type 1, which is a specific neurocristopathy condition.\n\n2. **assay**: \"transcriptomics\" \u2192 \"RNA-seq\"\n   - Transcriptomics is a broad term for studying the transcriptome. Narrowed to RNA-seq, which is the most common specific transcriptomics method.\n\n3. **tumorType**: \"neurolemmoma\" \u2192 \"Schwannoma\"\n   - Neurolemmoma is an older synonym for schwannoma. Replaced with the precise, standard terminology \"Schwannoma\" from the controlled vocabulary.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3056,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 913
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_017aqGF87bXrZmH52RvuERvN",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "I need to narrow the broad synonyms in the input data to more specific terms from the Target Schema.\n\nLet me analyze each field:\n\n1. **diagnosis**: \"neurocristopathy\"\n   - Neurocristopathy is a broad term referring to disorders of neural crest-derived tissues\n   - Looking at the enum values, I can see conditions like:\n     - Neurofibromatosis type 1\n     - Schwannomatosis variants (22q-related, LZTR1-related, NF2-related, SMARCB1-related)\n     - Vestibular Schwannoma\n     - Sporadic Schwannoma\n   - Neurocristopathies include these conditions. The most common and well-known neurocristopathy in this list would be \"Neurofibromatosis type 1\", which is a prototypical neural crest disorder.\n   - However, I should be careful - if the context is unclear, I might need to choose something more general. But \"neurocristopathy\" is indeed broad and could refer to several conditions in the list.\n   - Given that this is about narrowing, and NF1 is one of the most common neurocristopathies, \"Neurofibromatosis type 1\" would be a reasonable narrowing.\n\n2. **assay**: \"transcriptomics\"\n   - This is already in the enum list as \"transcriptomics\"\n   - Wait, let me check... yes, \"transcriptomics\" is listed in the assay enum\n   - However, the task says to narrow broad terms. \"Transcriptomics\" is quite broad.\n   - Looking at more specific transcriptomics methods in the list:\n     - RNA-seq\n     - scRNA-seq\n     - single cell RNA-seq\n     - single-cell RNA-seq\n     - whole transcriptome sequencing\n     - lncRNA-seq\n     - miRNA-seq\n     - small RNA-seq\n     - spatial transcriptomics\n   - The most common and standard form of transcriptomics is \"RNA-seq\"\n   - So narrowing \"transcriptomics\" to \"RNA-seq\" would be appropriate\n\n3. **tumorType**: \"neurolemmoma\"\n   - Neurolemmoma is an older/alternative term for schwannoma\n   - In the enum, I can see \"Schwannoma\" is listed\n   - This is a clear case of narrowing an alternative/synonym to the preferred term \"Schwannoma\"\n\nSo my corrections map the input terms to their most appropriate specific values: diagnosis becomes \"Neurofibromatosis type 1\", assay becomes \"RNA-seq\", and tumorType becomes \"Schwannoma\".",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"RNA-seq\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"neurocristopathy\" \u2192 \"Neurofibromatosis type 1\"\n   - Neurocristopathy is a broad term for disorders of neural crest-derived tissues. Narrowed to Neurofibromatosis type 1, which is a specific neurocristopathy condition.\n\n2. **assay**: \"transcriptomics\" \u2192 \"RNA-seq\"\n   - Transcriptomics is a broad term for studying the transcriptome. Narrowed to RNA-seq, which is the most common specific transcriptomics method.\n\n3. **tumorType**: \"neurolemmoma\" \u2192 \"Schwannoma\"\n   - Neurolemmoma is an older synonym for schwannoma. Replaced with the precise, standard terminology \"Schwannoma\" from the controlled vocabulary."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3056,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 913
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "NF2-related schwannomatosis",
          "assay": "RNA-seq",
          "tumorType": "schwannoma"
        },
        "token_usage": {
          "input_tokens": 3056,
          "output_tokens": 913,
          "total_tokens": 3969
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 9,
        "input": {
          "diagnosis": "phakomatosis",
          "assay": "viability assay",
          "tumorType": "tumor of cranial and spinal nerves"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Rationale for narrowing:**\n\n1. **diagnosis**: \"phakomatosis\" (broad term for neurocutaneous syndromes) \u2192 \"Neurofibromatosis type 1\" - This is the most common phakomatosis in the context of this schema, which focuses on neurofibromatosis and schwannomatosis conditions.\n\n2. **assay**: \"viability assay\" (general term) \u2192 \"cell viability assay\" - This is the most specific and commonly used viability assay term from the controlled terminology.\n\n3. **tumorType**: \"tumor of cranial and spinal nerves\" (broad anatomical description) \u2192 \"Schwannoma\" - Schwannomas are the most common tumors arising from cranial and spinal nerve sheaths, making this the most appropriate specific narrowing from the available controlled terminology.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3060,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1343
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01LPPuPdzjMvNmkxADQSUUVJ",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "I need to analyze the input data and narrow down the broad terms to more specific ones from the controlled terminology in the Target Schema.\n\nInput data:\n1. \"diagnosis\": \"phakomatosis\" - This is a broad term for neurocutaneous syndromes\n2. \"assay\": \"viability assay\" - This is a general term for assays measuring cell viability\n3. \"tumorType\": \"tumor of cranial and spinal nerves\" - This is a broad term for nerve tumors\n\nLet me look at the available options in the Target Schema:\n\nFor \"diagnosis\":\n- Phakomatosis is a broad term that includes neurofibromatosis and schwannomatosis conditions\n- Available options include: \"Neurofibromatosis type 1\", \"NF2-related schwannomatosis\", \"Schwannomatosis\", \"Vestibular Schwannoma\", \"Sporadic Schwannoma\", etc.\n- Since \"phakomatosis\" is very broad and could refer to several conditions, and I don't have more specific information, I should look for the most general applicable term or \"Unknown\"\n- Actually, looking at the options, there's no single specific match. The most common phakomatoses in this schema would be NF1 or schwannomatosis-related conditions. However, without more context, I might need to use \"Unknown\" or look for a more general option.\n- Wait, there's \"Not Applicable\" and \"Unknown\" as options. Since phakomatosis is too broad and encompasses multiple conditions listed, \"Unknown\" might be appropriate, or I could narrow to one of the specific conditions if there's a most common interpretation.\n- Actually, in the context of this schema which focuses on neurofibromatosis and schwannomatosis, \"phakomatosis\" likely refers to one of these. The most common would be \"Neurofibromatosis type 1\" but that's making an assumption. Let me reconsider - the task is to narrow broad terms, so I should pick the most appropriate specific term. Given the context of the schema, \"Neurofibromatosis type 1\" is one of the most common phakomatoses in this domain.\n\n\n- \"cell viability assay\" appears to be the most straightforward narrowing of the general viability assay term.\n- The nerve tumor classification could map to several options like Schwannoma, Neurofibroma, Vestibular Schwannoma, or Malignant Peripheral Nerve Sheath Tumor depending on the specific location and characteristics.\n\nI'm reconsidering the diagnosis field now. The instructions ask me to narrow broad synonyms, and \"Phakomatosis\" is quite general - it encompasses NF1, NF2, and various other neurocutaneous syndromes. Looking at what's available in the schema, there are multiple NF-related options to choose from.\n\nWithout additional clinical context, I can't definitively determine which specific phakomatosis applies. NF1 is the most prevalent form, which makes it a reasonable choice. Alternatively, \"Unknown\" might be more appropriate if I'm uncertain about the specific subtype. I'll select \"Neurofibromatosis type 1\" given its frequency, though I acknowledge this involves some interpretation.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Rationale for narrowing:**\n\n1. **diagnosis**: \"phakomatosis\" (broad term for neurocutaneous syndromes) \u2192 \"Neurofibromatosis type 1\" - This is the most common phakomatosis in the context of this schema, which focuses on neurofibromatosis and schwannomatosis conditions.\n\n2. **assay**: \"viability assay\" (general term) \u2192 \"cell viability assay\" - This is the most specific and commonly used viability assay term from the controlled terminology.\n\n3. **tumorType**: \"tumor of cranial and spinal nerves\" (broad anatomical description) \u2192 \"Schwannoma\" - Schwannomas are the most common tumors arising from cranial and spinal nerve sheaths, making this the most appropriate specific narrowing from the available controlled terminology."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3060,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1343
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "3D microtissue viability",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3060,
          "output_tokens": 1343,
          "total_tokens": 4403
        },
        "tool_calls": [],
        "tool_execution_history": []
      }
    ],
    "metrics": {
      "total_samples": 10,
      "successful_runs": 10,
      "failed_runs": 0,
      "success_rate": 1.0,
      "average_score": 0.4666666666666666,
      "min_score": 0.3333333333333333,
      "max_score": 1.0,
      "num_scored": 10
    },
    "duration_seconds": 174.17926335334778,
    "token_usage": {
      "input_tokens": 30562,
      "output_tokens": 10390,
      "total_tokens": 40952
    }
  }
}